Chlorambucil dosage in frequently relapsingnephrotic syndrome: A controlled clinical trial

A controlled clinical trial was performed using two dosage regimens of chlorambucil to treat childrenwith frequently relapsing nephrotic syndrome. All children concurrently received prednisone (60 mg/m 2 on alternate days). Ten children (Group I) were given chlorambucil as a stable dose (0.2 mg/kg/day) for 56 to 60 days, and 11 children (Group II) received increasing doses (0.2 to 0.63 mg/kg/day) for 42 to 77 days. Two children in each group subsequently relapsed. Follow-up averaged 28.6 and 27.2 months in Groups I and II, respectively. Three children in Group II developed infectious complications. The data indicate that a stable dosage regimen for chlorambucil is as effective as an increasing dose regimen in achieving long-term remission of frequently relapsing nephrotic syndrome.